MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

• Status: Completed
• Trial end date: 2019-04-16
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medy-Tox
• Treatments: Botulinum Toxins, Type A

Criteria

Inclusion Criteria:

• subject who aged 20 to less than 65 years

• subject with benign masseteric hypertrophy

Exclusion Criteria:

• subject not appropriate for participating in this study according to the investigator's opinion

• subject with known an anaphylactic response to BoNT/A and other involved ingredients of Investigational product